Prime Medicine, Inc（PRME）財務資料PRMEPrime Medicine, Inc

Evaluating the bottom line, Prime Medicine, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -3750.87%, while the net margin is -3648.96%. These profitability ratios, combined with a Return on Equity (ROE) of -373.29%, provide a clear picture of how effectively PRME converts its operational activities into shareholder value.

In the context of the broader market, PRME competes directly with industry leaders such as IAM and AURA. With a market capitalization of $694.67M, it holds a significant position in the sector. When comparing efficiency, PRME's gross margin of 100.00% stands against IAM's N/A and AURA's N/A. Such benchmarking helps identify whether Prime Medicine, Inc. is trading at a premium or discount relative to its financial performance.

Despite significant net losses, Prime Medicine has maintained a gross margin of 100% across recent quarters, indicating strong potential for profitability once revenues increase.